Table 1 Baseline characteristics of eyes of patients with DME receiving intravitreal anti-VEGF therapy
Characteristic | n (%) |
|---|---|
Sex | |
Male | 18 (56%) |
Female | 14 (44%) |
Number of anti-VEGF injections | |
3 | 4 (7%) |
4 | 20 (36%) |
5 | 21 (37%) |
6 | 11 (20%) |
Anti-VEGF agent used | |
Bevacizumab | 44 (78%) |
Ranibizumab | 2 (4%) |
Aflibercept | 2 (4%) |
Mixed | 8 (14%) |
Severity of diabetic retinopathy (ETDRS) | |
NPDR mild | 2 (4%) |
NPDR moderate | 16 (28%) |
NPDR severe | 20 (36%) |
PDR early | 12 (21%) |
PDR high risk | 6 (11%) |
Underwent panretinal photocoagulation | |
Yes | 27 (48%) |
No | 29 (52%) |